Initiation of Oseltamivir in Critically Ill Patients: Variations in Prescribing Practices

Abstract

Get full access to this article

View all access options for this article.

References

Uyeki

Bernstein

Bradley

, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2018;68:e1-e47. doi:10.1093/cid/ciy866

Oseltamivir phosphate. Package insert. Zydus Pharmaceuticals, Inc; 2019.

Muthuri

Venkatesan

Myles

, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med. 2014;2:395-404. doi:10.1016/S2213-2600(14)70041-4

Lytras

Mouratidou

Andreopoulou

Bonovas

Tsiodras

Effect of early oseltamivir treatment on mortality in critically ill patients with different types of influenza: a multiseason cohort study. Clin Infect Dis. 2019;69:1896-1902. doi:10.1093/cid/ciz101

Louie

Yang

Acosta

, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis. 2012;55:1198-1204. doi:10.1093/cid/cis636